Anterogen Co Ltd
065660
Company Profile
Business description
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.
Contact
Namsung Plaza, Gasan-dong
405, 130, Digital-ro, Geumcheon-gu
Seoul08589
KORT: +82 221040391
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,044.20 | 70.50 | 0.79% |
| CAC 40 | 8,474.86 | 137.57 | 1.65% |
| DAX 40 | 25,580.88 | 540.60 | 2.16% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,652.87 | 174.53 | 1.67% |
| HKSE | 23,371.19 | 316.16 | 1.37% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,243.68 | 510.53 | 0.74% |
| NZX 50 Index | 13,607.72 | 25.53 | 0.19% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,840.90 | 71.60 | 0.82% |
| SSE Composite Index | 4,057.11 | 28.21 | 0.70% |